D J Dairaghi

Summary

Publications

  1. ncbi Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose
    D J Dairaghi
    ChemoCentryx, Inc, Mountain View, California, USA
    Clin Pharmacol Ther 89:726-34. 2011
  2. ncbi CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
    Daniel J Dairaghi
    ChemoCentryx Inc, 850 Maude Ave, Mountain View, CA 94043, USA
    Blood 120:1449-57. 2012
  3. ncbi Cytomegalovirus encodes a potent alpha chemokine
    M E Penfold
    Aviron, 297 Bernardo Avenue, Mountain View, CA 94043, USA
    Proc Natl Acad Sci U S A 96:9839-44. 1999
  4. ncbi HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines
    D J Dairaghi
    Divisions of Discovery Biology and Molecular Pharmacology, ChemoCentryx, San Carlos, California 94070, USA
    J Biol Chem 274:21569-74. 1999
  5. ncbi Characterization of the rhesus cytomegalovirus US28 locus
    M E T Penfold
    ChemoCentryx, San Carlos, California 94070, USA
    J Virol 77:10404-13. 2003
  6. ncbi Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK
    J Gosling
    Divisions of Discovery Biology and Molecular Pharmacology, ChemoCentryx, San Carlos, CA 94070, USA
    J Immunol 164:2851-6. 2000

Collaborators

Detail Information

Publications6

  1. ncbi Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose
    D J Dairaghi
    ChemoCentryx, Inc, Mountain View, California, USA
    Clin Pharmacol Ther 89:726-34. 2011
    ..The comparison of the properties of CCX354 with those published for other CCR1 antagonists has informed the dose selection for ongoing clinical development of CCX354 in rheumatoid arthritis (RA)...
  2. ncbi CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
    Daniel J Dairaghi
    ChemoCentryx Inc, 850 Maude Ave, Mountain View, CA 94043, USA
    Blood 120:1449-57. 2012
    ..These results provide a strong rationale for further development of CCR1 antagonists for the treatment of MM and associated osteolytic bone disease...
  3. ncbi Cytomegalovirus encodes a potent alpha chemokine
    M E Penfold
    Aviron, 297 Bernardo Avenue, Mountain View, CA 94043, USA
    Proc Natl Acad Sci U S A 96:9839-44. 1999
    ....
  4. ncbi HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines
    D J Dairaghi
    Divisions of Discovery Biology and Molecular Pharmacology, ChemoCentryx, San Carlos, California 94070, USA
    J Biol Chem 274:21569-74. 1999
    ..CCR8 may thus engage a specific subset of chemokines with the potential to regulate each other during viral infection and immune regulation...
  5. ncbi Characterization of the rhesus cytomegalovirus US28 locus
    M E T Penfold
    ChemoCentryx, San Carlos, California 94070, USA
    J Virol 77:10404-13. 2003
    ..5) to have a ligand binding profile similar to that of US28. In addition, we localized US28 and the rhesus CMV homolog RhUS28.5 to the envelope of infectious virions, suggesting a role in viral entry or cell tropism...
  6. ncbi Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK
    J Gosling
    Divisions of Discovery Biology and Molecular Pharmacology, ChemoCentryx, San Carlos, CA 94070, USA
    J Immunol 164:2851-6. 2000
    ..With its high affinity for CC chemokines and homology to CC receptors, we provisionally designate this new receptor CCR10...